In our first release of 2021, we integrate 10,078,746 evidence strings to build 7,385,188 target-disease associations between 14,416 diseases and 27,650 targets from the following 19 public resources and databases.
Evidence strings breakdown by data source:
- 794,360 genetic evidence from European Variation Archive (EVA)
- 388,346 genetic evidence from Open Targets Genetics Portal
- 2,418 genetic evidence from Gene2Phenotype
- 20,911 genetic evidence from the Genomics England PanelApp
- 1,187 genetic evidence from ClinGen
- 183,643 genetic evidence from the PheWAS catalog
- 5,269 genetic evidence from UniProt Literature
- 10,457 somatic evidence from European Variation Archive (EVA)
- 3,342 somatic evidence from intOGen
- 61,666 somatic evidence from the Cancer Gene Census
- 442,053 drug evidence from ChEMBL
- 217,307 expression evidence from Expression Atlas
- 18,393 affected pathway evidence from Reactome
- 74,546 affected pathway evidence from SLAPenrich
- 308 affected pathway evidence from PROGENy
- 408 systems biology evidence from SysBio
- 1,846 CRISPR-Cas9 (Cancer Cell Lines) evidence from Behan et al. 2019
- 710,319 mouse model evidence from PhenoDigm
- 6,699,914 scientific literature evidence from co-occurence mining in Europe PMC
Key highlights for this release include:
- Data updates from ChEMBL, ClinGen, Europe PMC. EVA, Gene2Phenotype, PhenoDigm, Reactome, UniProt
- Updates to our COVID-19 Target Prioritisation Tool
- Preview link to Beta release of new version of Platform
For more details, check our 21.02 release blog post and 21.02 technical notes.